Aprea Therapeutics, Inc. (APRE) Net income 2017–2025
Aprea Therapeutics, Inc. (APRE) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$12.6MFY2025 · since FY2017: -$15.2M → -$12.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.6M | +2.8% |
| FY2024 | -$13.0M | +9.3% |
| FY2023 | -$14.3M | +87.3% |
| FY2022 | -$112.7M | -203.4% |
| FY2021 | -$37.1M | +30.6% |
| FY2020 | -$53.5M | -90.6% |
| FY2019 | -$28.1M | -80.7% |
| FY2018 | -$15.5M | -2.2% |
| FY2017 | -$15.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More APRE financial trends
APRE RevenueAPRE Net marginAPRE Gross profitAPRE Gross marginAPRE Operating incomeAPRE Operating marginAPRE Operating cash flowAPRE Free cash flowAPRE Capital expendituresAPRE Return on equityAPRE Stock buybacksAPRE Dividends paidAPRE Total assetsAPRE Total liabilitiesAPRE Shareholders’ equityAPRE overview →